Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK study of PF-06463922 (Lorbrena) in healthy volunteers
NCT02569554Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2015
- Primary completion
- Apr 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoints: Area under the plasma concentration-time curve from time zero to infinity at 3 months and Maximum plasma concentration at 3 months. Started Dec 2015; status: completed.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02569554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02569554.